Which has stronger earnings and valuation, QNCX or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A

Is QNCX or RNTX more profitable?

Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Rein Therapeutics N/A N/A -68.14%

Is GANX or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Quince Therapeutics N/A N/A -67.99%

Do analysts prefer SCLX or QNCX?

Quince Therapeutics has a consensus price target of $568.40, indicating a potential upside of 2,330.10%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.27

Is SCLX or QNCX more profitable?

Quince Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% Quince Therapeutics N/A N/A -67.99%

Does the media favor SCLX or QNCX?

In the previous week, Quince Therapeutics had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Quince Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.67 beat Quince Therapeutics' score of 0.50 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PMVP or QNCX?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A

Is PMVP or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -68.98% -62.70% Quince Therapeutics N/A N/A -67.99%

Does the media favor PMVP or QNCX?

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.86 beat Quince Therapeutics' score of 0.50 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QNCX or PLRX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Pliant Therapeutics N/A -58.11% -44.37%

Does the media refer more to QNCX or PLRX?

In the previous week, Pliant Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Quince Therapeutics. Pliant Therapeutics' average media sentiment score of 0.55 beat Quince Therapeutics' score of 0.50 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quince Therapeutics (QNCX) Competitors

$23.39 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$23.30 -0.09 (-0.38%)

As of 07/31/2026 07:38 PM Eastern

Compare

QNCX vs. RNTX, GANX, SCLX, PMVP, and PLRX

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include Rein Therapeutics (RNTX), Gain Therapeutics (GANX), Scilex (SCLX), PMV Pharmaceuticals (PMVP), and Pliant Therapeutics (PLRX).

How does Quince Therapeutics compare to Rein Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Quince Therapeutics had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 2 mentions for Quince Therapeutics and 0 mentions for Rein Therapeutics. Quince Therapeutics' average media sentiment score of 0.50 beat Rein Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Positive
Rein Therapeutics	Neutral

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Quince Therapeutics currently has a consensus price target of $568.40, indicating a potential upside of 2,330.10%. Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 713.67%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Quince Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rein Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Quince Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Rein Therapeutics	N/A	N/A	-68.14%

Summary

Quince Therapeutics beats Rein Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Quince Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 346.43%. Quince Therapeutics has a consensus target price of $568.40, suggesting a potential upside of 2,330.10%. Given Quince Therapeutics' higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

In the previous week, Quince Therapeutics had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Quince Therapeutics and 0 mentions for Gain Therapeutics. Quince Therapeutics' average media sentiment score of 0.50 beat Gain Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Quince Therapeutics	Positive

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than Quince Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,433.04	-$20.16M	-$0.58	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

Quince Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Quince Therapeutics	N/A	N/A	-67.99%

Summary

Quince Therapeutics beats Gain Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

In the previous week, Quince Therapeutics had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Quince Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.67 beat Quince Therapeutics' score of 0.50 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.7% of Scilex shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quince Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Quince Therapeutics	N/A	N/A	-67.99%

Quince Therapeutics has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.87	-$358.73M	-$40.47	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

Quince Therapeutics has a consensus price target of $568.40, indicating a potential upside of 2,330.10%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Scilex has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Summary

Quince Therapeutics beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Quince Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Quince Therapeutics	N/A	N/A	-67.99%

PMV Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 260.36%. Quince Therapeutics has a consensus price target of $568.40, suggesting a potential upside of 2,330.10%. Given Quince Therapeutics' higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

PMV Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 2 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.86 beat Quince Therapeutics' score of 0.50 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

PMV Pharmaceuticals beats Quince Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Quince Therapeutics compare to Pliant Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Quince Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Quince Therapeutics. Pliant Therapeutics' average media sentiment score of 0.55 beat Quince Therapeutics' score of 0.50 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Pliant Therapeutics	$1.58M	40.76	-$149.34M	-$1.84	N/A

Quince Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Pliant Therapeutics	N/A	-58.11%	-44.37%

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Quince Therapeutics currently has a consensus price target of $568.40, indicating a potential upside of 2,330.10%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 188.46%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Quince Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Quince Therapeutics beats Pliant Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.92M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-0.11	7.38	282.30	24.66
Price / Sales	N/A	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	-0.18	16.96	10.98	6.07
Net Income	-$83.98M	-$12.56M	$3.49B	$347.99M
7 Day Performance	31.04%	-1.76%	-0.60%	-0.44%
1 Month Performance	35.75%	-8.38%	-5.20%	-4.81%
1 Year Performance	-93.04%	48.40%	62.01%	18.61%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	2.9118 of 5 stars	$23.39 flat	$568.40 +2,330.1%	-93.0%	$22.92M	N/A	N/A	60
RNTX Rein Therapeutics	3.1565 of 5 stars	$0.84 -2.1%	$6.00 +610.9%	-33.6%	$73.74M	N/A	N/A	9	Gap Up
GANX Gain Therapeutics	1.9491 of 5 stars	$1.63 -4.7%	$7.50 +360.1%	+16.7%	$72.94M	$50K	N/A	20	Positive News
SCLX Scilex	0.4775 of 5 stars	$7.64 -9.5%	N/A	-50.3%	$71.67M	$30.25M	N/A	80	Gap Up
PMVP PMV Pharmaceuticals	3.6034 of 5 stars	$1.28 -4.5%	$4.00 +212.5%	-20.7%	$71.46M	N/A	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. RNTX, GANX, SCLX, PMVP, and PLRX

How does Quince Therapeutics compare to Rein Therapeutics?

Summary

How does Quince Therapeutics compare to Gain Therapeutics?

Summary

How does Quince Therapeutics compare to Scilex?

Summary

How does Quince Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Quince Therapeutics compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. RNTX, GANX, SCLX, PMVP, and PLRX

How does Quince Therapeutics compare to Rein Therapeutics?

Does the media favor QNCX or RNTX?

Do insiders & institutionals hold more shares of QNCX or RNTX?

Do analysts prefer QNCX or RNTX?

Which has stronger earnings and valuation, QNCX or RNTX?

Which has more risk & volatility, QNCX or RNTX?

Is QNCX or RNTX more profitable?

Summary

How does Quince Therapeutics compare to Gain Therapeutics?

Do analysts prefer GANX or QNCX?

Does the media prefer GANX or QNCX?

Do insiders & institutionals hold more shares of GANX or QNCX?

Which has more volatility and risk, GANX or QNCX?

Which has stronger valuation and earnings, GANX or QNCX?

Is GANX or QNCX more profitable?

Summary

How does Quince Therapeutics compare to Scilex?

Does the media favor SCLX or QNCX?

Do institutionals & insiders have more ownership in SCLX or QNCX?

Is SCLX or QNCX more profitable?

Which has better valuation and earnings, SCLX or QNCX?

Do analysts prefer SCLX or QNCX?

Which has more risk & volatility, SCLX or QNCX?

Summary

How does Quince Therapeutics compare to PMV Pharmaceuticals?

Is PMVP or QNCX more profitable?

Do analysts prefer PMVP or QNCX?

Which has more volatility & risk, PMVP or QNCX?

Does the media favor PMVP or QNCX?

Which has stronger earnings and valuation, PMVP or QNCX?

Do insiders & institutionals hold more shares of PMVP or QNCX?

Summary

How does Quince Therapeutics compare to Pliant Therapeutics?

Which has more volatility and risk, QNCX or PLRX?

Does the media refer more to QNCX or PLRX?

Which has better earnings and valuation, QNCX or PLRX?

Is QNCX or PLRX more profitable?

Do institutionals & insiders have more ownership in QNCX or PLRX?

Do analysts rate QNCX or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools